ZRB1535
Anti-SLC10A1 Antibody, clone 1B12 ZooMAb® Rabbit Monoclonal
recombinant, expressed in HEK 293 cells
Synonym(s):
Sodium/bile acid cotransporter;Cell growth-inhibiting gene 29 protein;Na(+)/bile acid cotransporter;Na(+)/taurocholate transport protein;Sodium/taurocholate cotransporting polypeptide;Solute carrier family 10 member 1
Sign Into View Organizational & Contract Pricing
All Photos(9)
About This Item
UNSPSC Code:
12352203
NACRES:
NA.43
Pricing and availability is not currently available.
Recommended Products
biological source
rabbit
Quality Level
recombinant
expressed in HEK 293 cells
conjugate
unconjugated
antibody form
purified antibody
antibody product type
primary antibodies
clone
1B12, recombinant monoclonal
description
recombinant, expressed in HEK 293 cells
product line
ZooMAb® learn more
form
lyophilized
1 of 4
This Item | SAB5701676 | HPA039481 | HPA059282 |
|---|---|---|---|
| Quality Level 100 | Quality Level 100 | Quality Level 100 | Quality Level - |
| conjugate unconjugated | conjugate - | conjugate unconjugated | conjugate unconjugated |
| biological source rabbit | biological source rabbit | biological source rabbit | biological source rabbit |
| antibody form affinity isolated antibody | antibody form - | antibody form affinity isolated antibody | antibody form affinity isolated antibody |
| product line Prestige Antibodies® Powered by Atlas Antibodies | product line - | product line Prestige Antibodies® Powered by Atlas Antibodies | product line Prestige Antibodies® Powered by Atlas Antibodies |
| shipped in wet ice | shipped in wet ice | shipped in wet ice | shipped in wet ice |
General description
We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Specificity
Clone 1B12 is a ZooMAb® Rabbit recombinant monoclonal antibody that specifically detects Sodium/bile acid cotransporter (SLC10A1). It targets an epitope within 17 amino acids from the C-terminal region.
Immunogen
KLH-conjugated linear peptide corresponding to 17 amino acids from the C-terminal region of human Sodium/bile acid cotransporter (SLC10A1).
Application
Quality Control Testing
Evaluated by Western Blotting in Human liver tissue lysate.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected SLC10A1 in Human liver tissue lysate.
Tested applications
Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected recombinant Human SLC10A.
Enzyme Immunoassay Analysis (ELISA): Serial dilutions from a representative lot detected recombinant Human SLC10A1 protein.
Immunocytochemistry Analysis: 1:100 dilution from a representative lot detected SLC10A1 in A549 cells.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
Evaluated by Western Blotting in Human liver tissue lysate.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected SLC10A1 in Human liver tissue lysate.
Evaluated by Western Blotting in Human liver tissue lysate.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected SLC10A1 in Human liver tissue lysate.
Tested applications
Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected recombinant Human SLC10A.
Enzyme Immunoassay Analysis (ELISA): Serial dilutions from a representative lot detected recombinant Human SLC10A1 protein.
Immunocytochemistry Analysis: 1:100 dilution from a representative lot detected SLC10A1 in A549 cells.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
Evaluated by Western Blotting in Human liver tissue lysate.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected SLC10A1 in Human liver tissue lysate.
Target description
Sodium/bile acid cotransporter (UniProt: Q14973; also known as Cell growth-inhibiting gene 29 protein, Na(+)/bile acid cotransporter, Na(+)/taurocholate transport protein, Sodium/taurocholate cotransporting polypeptide, Solute carrier family 10 member 1) is encoded by the SLC10A1 (also known as NTCP, GIG29) gene (Gene ID: 6554) in human. SLC10A1 is a multi-pass membrane glycoprotein with eight transmembrane domains. It is expressed exclusively on the basolateral membrane of hepatocytes and serves as a major high-affinity Na+-dependent transporter of conjugated bile salts from plasma into hepatocytes. It plays a key role in the enterohepatic circulation of bile salts necessary for the solubilization and absorption of dietary fat and fat-soluble vitamins. About 75% of the conjugated bile acids and about 50% of unconjugated bile acids are imported via this transporter. The inward Na+ gradient necessary for this process is maintained by a Na+/K+ ATP pump. This process is shown to be extremely efficient, with 75% to 90% first-pass clearance of bile acids from the sinusoidal blood. SLC10A1 exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. Mutations in SLC10A1 gene are reported to cause familial hypercholanemia 2 (FHCA2) that is characterized by persistently higher plasma levels of conjugated bile salts that is apparent from infancy associated with fat malabsorption and impaired absorption of fat-soluble vitamins. This ZooMAbZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Vaz, FM., et al. (2014). Hepatology. 61(1); 260-267).
Physical form
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
Reconstitution
Reconstitute lyophilized antibody pellet with 25μL of ultrapure water or Phosphate Buffered Saline (PBS). Please refer to our reconstitution protocol and the specific application guidance on the suggested starting dilutions and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Don't see the Right Version?
If you require a particular version, you can look up a specific certificate by the Lot or Batch number.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Matthew H Crouthamel et al.
Arteriosclerosis, thrombosis, and vascular biology, 33(11), 2625-2632 (2013-08-24)
Elevated serum phosphate has emerged as a major risk factor for vascular calcification. The sodium-dependent phosphate cotransporter, PiT-1, was previously shown to be required for phosphate-induced osteogenic differentiation and calcification of cultured human vascular smooth muscle cells (VSMCs), but its
Matthew R Weir et al.
Journal of clinical hypertension (Greenwich, Conn.), 16(12), 875-882 (2014-10-21)
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure (BP) and osmotic diuresis- and intravascular volume reduction-related adverse events (AEs) were evaluated using pooled data from four placebo-controlled, phase 3 studies in patients with type 2
Luciano Candilio et al.
Heart (British Cardiac Society), 101(3), 185-192 (2014-09-26)
Remote ischaemic preconditioning (RIPC), using brief cycles of limb ischaemia/reperfusion, is a non-invasive, low-cost intervention that may reduce perioperative myocardial injury (PMI) in patients undergoing cardiac surgery. We investigated whether RIPC can also improve short-term clinical outcomes. One hundred and
George G S Sandor et al.
International journal of cardiology, 179, 470-475 (2014-12-04)
Patients with Marfan (MFS) and Loeys-Dietz (LDS) syndromes have been shown to have abnormal aortic biophysical properties. The purpose of this study was to compare the effects of 12-months of therapy with atenolol or losartan on vascular function in young
Karen Sliwa et al.
Heart (British Cardiac Society), 100(24), 1967-1974 (2014-09-18)
Lack of evidence-based data on the spectrum of cardiovascular disease (CVD) in pregnancy or in the postpartum period, as well as on maternal and fetal outcome, provides challenges for treating physicians, particularly in areas of low resources. The objectives of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
